Jiangsu Hengrui Pharmaceuticals Co., Ltd. (Hengrui Pharma) is a China‑based, research‑driven pharmaceutical company headquartered in Lianyungang, Jiangsu, and listed on the Shanghai Stock Exchange. It develops and manufactures innovative medicines and high‑quality generics spanning oncology, anesthesia and pain management, cardiovascular and metabolic diseases, anti‑infectives, and diagnostic imaging.
Hengrui integrates discovery chemistry, process development, and scale manufacturing across small‑molecule drugs, biologics, active pharmaceutical ingredients (APIs), and finished dosage forms. The company is a significant domestic producer of non‑ionic iodinated contrast media and related intermediates, linking its activities closely to the chemical value chain. Its operations include multiple R&D and manufacturing sites in China, with products supplied to the domestic market and exported to international markets.
Beyond commercialized products, Hengrui advances a pipeline that includes targeted therapies and immuno‑oncology agents, and it engages in collaborations and out‑licensing for select assets. The company’s role in the chemical industry centers on the large‑scale synthesis of APIs, intermediates, and specialty radiographic agents, supported by process optimization and quality systems for regulated markets.
To provide comprehensive coverage, we aggregate data and news under the name Hengrui Pharma, encompassing the following company names, divisions, and related entities:
Hengrui Medicine.
This list encompasses current and former names, alternate names, and key divisions associated with Hengrui Pharma, ensuring you can easily find all relevant information under a single, unified profile.
